DataMeds AI files draft information statement (Form PRE 14C)

DataMeds AI shareholders authorized an amendment to add 1,000,000 shares of blank-check preferred stock. Board gained flexibility to set terms for new preferred series, including voting, dividend, liquidation, conversion rights, restrictions. Plan includes designating 25,000 shares as Series A Convertible Preferred Stock tied to conversion of May 2026 Notes. May 2026 Notes total principal of $21,132,812.50; PIPE Warrants cover up to 8,298,225 common shares at $7.50. Shareholders also authorized five directors, ratified Suri & Co. as auditor for fiscal 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046610), on October 09, 2026, and is solely responsible for the information contained therein